William Blair William Blair Downgrades Lucira Health to Market Perform As a result of the downgrade, the bank also significantly reduced revenue and volume estimates for 2021 and 2022. William Blair Initiates Coverage of 10x Genomics With Outperform Rating Analysts for the investment bank, which co-managed a recent 10x stock offering, said the company could "redefine the way biological analysis is performed." Roche to Acquire GenMark Diagnostics for $1.8B Under the acquisition agreement, expected to close in Q2, Roche will acquire all outstanding shares of GenMark's common stock for $24.05 per share. 10x Genomics Prices Upsized $440M Public Offering The firm is offering an additional 500,000 shares of Class A stock, bringing the total to 4 million shares, offered at $110 per share. 10x Genomics to Sell 3.5M Shares in Public Offering The single-cell and spatial genomics firm is seeking to raise more money from the markets a year after its $410.8 million IPO. Aug 11, 2020 JP Morgan, Cowen, William Blair Initiate Coverage of Berkeley Lights Jul 16, 2020 Adaptive Biotechnologies to Raise $240M in Public Stock Offering May 11, 2020 William Blair Upgrades Meridian Bioscience to Outperform Jan 24, 2020 Adaptive Biotechnologies Prices Public Offering of Stock Jan 21, 2020 Adaptive Biotechnologies Announces Preliminary FY19 Revenue Increase, $257M Stock Offering Jul 26, 2018 Veracyte Prices $51.3M Public Offering Jan 5, 2018 Illumina Remains NGS Leader But Competitors Expected to Gain, Survey Finds Premium Jul 18, 2017 Investment Banks Upgrade Quidel Shares on Acquisition of Alere Assets May 21, 2015 Investment Banks Downgrade Bruker on Resignation of CFO May 1, 2015 William Blair Upgrades PacBio Shares on Technology Improvements, Expanded Applications Apr 21, 2015 Survey Finds High Interest in Long-Range Genome Data, Nanopore Tech While Illumina Rules NGS Market Premium Jan 20, 2015 Investment Banks Upgrade Fluidigm, Hologic Jun 23, 2014 William Blair Upgrades Sequenom to Outperform Aug 2, 2013 Piper Jaffray Upgrades PacBio Following Earnings Results Jul 25, 2013 William Blair Downgrades Sequenom, Citing Coding Issues and Increased Competition; Shares Down Sharply Jul 19, 2013 William Blair Begins Coverage of Waters with Market Perform Rating Jan 22, 2013 Analysts Speculate on Potential Life Technologies Sale Oct 25, 2012 Survey Indicates Life Tech Remains Leader of qPCR Research Market, But Faces Some Pricing Pressure Premium Sep 25, 2012 William Blair Initiates Coverage of Life Tech with Outperform May 29, 2012 William Blair Downgrades Complete Genomics Load More Breaking News FDA Revises SARS-CoV-2 Test Emergency Use Authorization Requirements to Account for Variants Geisinger Wins $5M NIH Grant to Develop Point-of-Care Genetic Diagnostic Tool Second Genome, Virginia Commonwealth University Partner on NASH Biomarker Discovery LGC Receives CE Mark for AccuPlex SARS-CoV-2, Flu A/B, RSV Reference Material Kit Esophageal Cancer Testing Firm Lucid Diagnostics Files For IPO Twist Bioscience, DeepCDR Collaborate on Antibody Library Design The Scan Booster for At-Risk The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk. Preprints OK to Mention Again Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications. Hundreds of Millions More to Share The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post. Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.